Alvotech and Stada add to strategic alliance through denosumab partnership [Seeking Alpha]
Alvotech (ALVO)
Company Research
Source: Seeking Alpha
Prolia/Xgeva (denosumab) medicines for osteoporosis and cancer-related bone loss respectively, the companies said on Tuesday. Alvotech ( ALVO ) will be responsible for development and manufacturing at its facility in Reykjavik, Iceland. Stada will become marketing authorization holder, upon approval of AVT03, and will assume semi-exclusive commercial rights in Europe, including Switzerland and the UK, as well as exclusive commercial rights in selected countries in Central Asia and the Middle East. In parallel with the commercial agreement for AVT03, the two partners have agreed to extend Stada's commercial rights to biosimilars to AbbVie's ( ABBV top-selling arthritis drug Humira (adalimumab) and Johnson & Johnson's ( JNJ Stelara (ustekinumab) to Commonwealth of Independent States countries in Central Asia. Alvotech ( ALVO ) will also regain commercial rights from STADA to AVT06, a proposed biosimilar to Eylea (aflibercept). Recommended For You More Trending News Recommend
Show less
Read more
Impact Snapshot
Event Time:
ALVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALVO alerts
High impacting Alvotech news events
Weekly update
A roundup of the hottest topics
ALVO
News
- Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe [Yahoo! Finance]Yahoo! Finance
- Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in EuropeGlobeNewswire
- Alvotech and STADA add to strategic alliance through denosumab partnership [Yahoo! Finance]Yahoo! Finance
- Alvotech and STADA add to strategic alliance through denosumab partnershipGlobeNewswire
- Alvotech enters refinancing agreement with $965M term loan facility [Seeking Alpha]Seeking Alpha
ALVO
Earnings
- 5/21/24 - Miss
ALVO
Sec Filings
- 6/18/24 - Form 6-K
- 6/14/24 - Form 6-K
- 6/14/24 - Form 424B5
- ALVO's page on the SEC website